What is Selank?
Selank is a synthetic heptapeptide, seven amino acids, developed in Russia and studied mainly for anxiety and stress-related symptoms. It is modeled on tuftsin, a natural peptide fragment with roles in immune signaling, which is why the research on it spans calm, mood, attention, and immunity rather than one lane.
In the literature it is usually described as an anxiolytic peptide: a compound aimed at lowering anxiety without the baggage of the drugs that usually do that job. Whether it earns that description is what the evidence tiers below sort out.
How does it work?
The proposed mechanism runs through GABA, the brain's main calming system, the same broad pathway benzodiazepines act on. A 2018 laboratory study reported that Selank works as a positive allosteric modulator of GABA receptors, enhancing the system's activity, but binding differently from benzodiazepines, which the authors suggest may explain why it does not appear to carry the same dependence and sedation profile.
A 2017 rat study added behavior to the receptor story, showing Selank enhanced the calming effect of diazepam under chronic stress, and the tuftsin lineage connects it to a wider family of peptides studied for immune-modulating activity. Mechanism and animal behavior, mapped; the human question comes next.
Why it matters
Anxiety medicine is stuck between two bad defaults: benzodiazepines that work fast but sedate and hook, and antidepressants that take weeks and blunt. A peptide that engages the calming system without dependence or sedation would be genuinely valuable, and that exact profile is what the Russian clinical work claims for Selank. The claim deserves both attention and scrutiny, which is the spirit of this article.
What the evidence shows, tier by tier
At the mechanism level: the 2018 GABA-modulation study and the 2017 tuftsin-family review establish how Selank plausibly acts and where it sits among related peptides.
At the animal level: the 2017 rat study showing potentiation of diazepam's calming effect under chronic stress.
At the human level: a small set of Russian trials. A 2008 study in generalized anxiety disorder and neurasthenia compared Selank against the benzodiazepine medazepam in 62 patients and reported comparable anxiolytic effect, plus anti-fatigue and mild stimulant qualities. A 2014 comparative trial in 60 patients with phobic-anxiety and somatoform disorders, against phenazepam, reported pronounced anxiolytic effect with a mild nootropic bonus, and calm persisting about a week after the last dose. Real comparative trials, small, and concentrated in the research tradition that developed the compound, with no large independent Western replication.
What people notice in practice
What users report, labeled honestly as experience rather than trial evidence, is a quiet loosening rather than sedation: the anxious edge coming off while the head stays clear, often within the first days of nasal or injectable use, sometimes with a focus lift consistent with the reported nootropic edge. Others feel nothing, and anxiety, like sleep and energy, responds generously to expectation.
The practice detail worth knowing: most real-world use is intranasal spray, while the trials used their own routes and settings, one more familiar gap between studied and used.
The pros and the cons
What's promising
- A plausible GABA mechanism that differs from benzodiazepine binding.
- Comparative human trials reporting benzodiazepine-level calm without the sedation profile.
- Reported anti-fatigue and mild focus benefits alongside the anxiolysis.
- No dependence signal in the published work.
What's uncertain
- The human trials are small and concentrated in one research tradition, with limited independent replication.
- No placebo-controlled Western trial exists at all.
- Long-term use is uncharacterized.
- Not approved by the FDA or EMA; approved and used regionally in Russia.
Worth considering
- Anxiety that impairs life deserves proper care first; peptides are not crisis tools.
- Interactions with existing psychiatric medication are physician territory.
- Intranasal practice use is a route the trials did not study.
- Sourcing quality, as always in the gray market, is half the product.
Why the evidence looks the way it does
Selank comes from the Soviet-then-Russian peptide research tradition, which produced real clinical studies published in Russian journals and almost no crossover into Western trial systems. That is a provenance fact, not a verdict: the studies exist and report what they report, and the independent replication that would settle the question has never been funded, because the molecule is regional, old, and unpatentable in the markets that fund big trials. Familiar economics, particular geography.
What the key studies tested
Our framing rule for evidence: a study tests one dose, one route, one population, one comparator. Where the evidence sits:
Preclinical & practice
The GABA mechanism work, the diazepam-potentiation rat study, and intranasal practice use.
Early trials
Comparative Russian trials against medazepam (62 patients) and phenazepam (60 patients).
Late-stage trials
None in Western trial systems.
Approved uses
Regional approval and use in Russia; none from the FDA or EMA.
Every study behind this article is filterable in our research library on the Science page.
Questions people ask
Is Selank like a benzodiazepine?
It works on the same broad calming system, GABA, but binds differently, and the comparative trials reported benzodiazepine-level anxiolysis without the sedation, and no dependence signal. That profile is exactly what makes it interesting and exactly what needs independent replication before being treated as established.
How solid are the Russian trials?
They are genuine comparative clinical studies, 60-plus patients each, published in the scientific literature, and they are small, from the tradition that developed the compound, and without Western placebo-controlled replication. Both halves are true at once, and honest reading holds them together rather than choosing one.
What is the connection to the immune system?
Selank is built on tuftsin, a natural immune-signaling peptide fragment, and the tuftsin family is studied for immune-modulating and anti-inflammatory activity. That lineage is why Selank research extends beyond anxiety into immune signaling and attention, though those threads are earlier-stage than the anxiolytic work.
Is Selank safe to try?
The published studies reported good tolerability and no dependence, within their limits of size and duration. The practical cautions are the usual ones plus one: gray-market sourcing, an unstudied intranasal route, and, importantly, anyone on psychiatric medication or with impairing anxiety belongs with a clinician before any experiment.
What to take away
If you remember five things from this article, make them these:
- Selank is a tuftsin-derived peptide with a plausible GABA mechanism distinct from benzodiazepine binding.
- Russian comparative trials report benzodiazepine-level calm without sedation or dependence.
- Those trials are small, regional, and unreplicated in Western placebo-controlled systems.
- Practice use is mostly intranasal, a route the studies never tested.
- Interesting is the right word; impairing anxiety still belongs with proper clinical care first.
The evidence
Selected peer-reviewed references, each verified against PubMed. Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Selank is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.